365542-77-4Relevant articles and documents
ANTIVIRAL SOX INHIBITORS
-
, (2022/03/09)
The present disclosure generally relates to antiviral compounds for use in treatment of viral associated diseases or conditions. The present disclosure also relates to processes for preparing the antiviral compounds, and uses or methods of treatment of viral associated diseases or conditions comprising the antiviral compounds. The present disclosure also provides antiviral compounds as inhibitors of SOX family transcription factors, and in particular 5 SOX18 transcription factor. In particular, the antiviral compounds are based on a biaryl benzoic acid scaffold according to Formula 1 as described herein.
Efficient synthesis of anacardic acid analogues and their antibacterial activities
Mamidyala, Sreeman K.,Ramu, Soumya,Huang, Johnny X.,Robertson, Avril A.B.,Cooper, Matthew A.
, p. 1667 - 1670 (2013/04/10)
Anacardic acid derivatives exhibit a broad range of biological activities. In this report, an efficient method for the synthesis of anacardic acid derivatives was explored, and a small set of salicylic acid variants synthesised retaining a constant hydrophobic element (a naphthyl tail). The naphthyl side chain was introduced via Wittig reaction and the aldehyde installed using directed ortho-metalation reaction of the substituted o-anisic acids. The failure of ortho-metalation using unprotected carboxylic acid group compelled us to use directed ortho-metalation in which a tertiary amide was used as a strong ortho-directing group. In the initial route, tertiary amide cleavage during final step was challenging, but cleaving the tertiary amide before Wittig reaction was beneficial. The Wittig reaction with protected carboxylic group (methyl ester) resulted in side-products whereas using sodium salt resulted in higher yields. The novel compounds were screened for antibacterial activity and cytotoxicity. Although substitution on the salicylic head group enhanced antibacterial activities they also enhanced cytotoxicity.
